Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/45911
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kopylov, Uri | - |
dc.contributor.author | Mantzaris, Gerassimos J. | - |
dc.contributor.author | Katsanos, Konstantinos H. | - |
dc.contributor.author | Reenaers, Cathérine | - |
dc.contributor.author | Ellul, Pierre | - |
dc.contributor.author | Rahier, Jean-François | - |
dc.contributor.author | Israeli, Eran | - |
dc.contributor.author | Lakatos, Péter László | - |
dc.contributor.author | Fiorino, Gionata | - |
dc.contributor.author | Cesarini, Monica | - |
dc.contributor.author | Tsianos, Epameinondas V. | - |
dc.contributor.author | Louis, Édouard | - |
dc.contributor.author | Ben-Horin, Shomron | - |
dc.date.accessioned | 2019-08-26T08:53:43Z | - |
dc.date.available | 2019-08-26T08:53:43Z | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Kopylov, U., Mantzaris, G. J., Katsanos, K. H., Reenaers, C., Ellul, P., Rahier, J. F., ...Ben-Horin, S. (2011). The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab. Alimentary Pharmacology & Therapeutics, 33(3), 349-357. | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar/handle/123456789/45911 | - |
dc.description.abstract | Background Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage due to loss of response. There are scant data regarding the efficacy of shortening the dosing interval to 6 weeks. Aim We sought to investigate the efficacy of a once every 6 weeks' strategy compared with dose-doubling. Methods This work was a multicentre retrospective study of infliximab-treated CD patients who required dose escalation. The clinical outcome of patients treated by intensification to 5 mg/kg/6 weeks (6-week group) was compared with the outcome of patients whose infliximab was double-dosed (10 mg/kg/8 weeks or 5 mg/kg/4 weeks). Results Ninety-four patients (mean age: 29.8 years) were included in the study, 55 (59%) in the 6-week group and 39 (41%) in the double-dose group. Demographics and disease characteristics were similar between the two groups, although patients with re-emerging symptoms 5-7 weeks postinfusion were more likely to receive 5 mg/kg/6 weeks dosing (OR: 3.4, 95% CI: 1.4-8.8, P < 0.01). Early response to dose-intensification occurred in 69% of patients in the 6-week group and 67% in the double-dose group (P = N.S.). Regained response was maintained for 12 months in 40% compared with 29% of the patients respectively (P = N.S.). Conclusion In CD patients who lost response to standard infliximab dose, especially when symptoms re-emerge 5-7 weeks postinfusion, shortening the dosing interval to 6 weeks appears to be at least as effective as doubling the dose to 10 mg/kg or halving the infusion intervals to once in 4 weeks. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Blackwell Publishing Ltd | en_GB |
dc.rights | info:eu-repo/semantics/restrictedAccess | en_GB |
dc.subject | Crohn's disease -- Research | en_GB |
dc.subject | Crohn's disease -- Patients -- Case studies | en_GB |
dc.subject | Infliximab | en_GB |
dc.subject | Infliximab -- Therapeutic use | en_GB |
dc.subject | Gastrointestinal agents | en_GB |
dc.title | The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab | en_GB |
dc.type | article | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
dc.identifier.doi | 10.1111/j.1365-2036.2010.04523.x | - |
dc.publication.title | Alimentary Pharmacology & Therapeutics | en_GB |
Appears in Collections: | Scholarly Works - FacM&SMed |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
The_efficacy_of_shortening_the_dosing_interval_to_once_every_six_weeks_in_Crohn’s_patients_losing_response_to_maintenance_dose_of_infliximab_2011.pdf Restricted Access | 202.29 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.